Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Given Average Recommendation of “Buy” by Brokerages

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) has been given a consensus recommendation of “Buy” by the ten ratings firms that are presently covering the firm, MarketBeat.com reports. Eight investment analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $46.4286.

A number of analysts have commented on the stock. B. Riley Financial assumed coverage on shares of Ascentage Pharma Group International in a research note on Wednesday, June 10th. They set a “buy” rating and a $45.00 price objective for the company. Raymond James Financial reissued a “buy” rating on shares of Ascentage Pharma Group International in a research report on Wednesday, June 10th. Finally, BTIG Research restated a “buy” rating and set a $48.00 price target on shares of Ascentage Pharma Group International in a report on Friday, August 21st.

Institutional Trading of Ascentage Pharma Group International

Hedge funds and other institutional investors have recently modified their holdings of the business. Citadel Advisors LLC purchased a new position in shares of Ascentage Pharma Group International during the third quarter valued at $383,000. Hsbc Holdings PLC purchased a new stake in Ascentage Pharma Group International in the 2nd quarter worth about $391,000. Finally, UBS Group AG lifted its stake in Ascentage Pharma Group International by 149.4% in the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after acquiring an additional 10,988 shares in the last quarter.

Ascentage Pharma Group International Price Performance

Shares of Ascentage Pharma Group International stock opened at $16.90 on Thursday. The stock’s fifty day moving average is $18.18 and its 200-day moving average is $21.04. The company has a quick ratio of 1.18, a current ratio of 1.22 and a debt-to-equity ratio of 1.09. Ascentage Pharma Group International has a 12-month low of $16.36 and a 12-month high of $42.48.

Ascentage Pharma Group International (NASDAQ:AAPG) last released its quarterly earnings results on Wednesday, August 19th. The company reported ($0.65) earnings per share for the quarter. The company had revenue of $22.24 million during the quarter. Equities research analysts predict that Ascentage Pharma Group International will post -2.26 EPS for the current fiscal year.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.